Wockhardt Pharma shares rebounded after a five-day fall, with SEBI analyst Deepak Pal flagging strong support at ₹1,400 and the 200-day EMA. He sees scope for the stock to rise towards ₹1,550-1,610 if momentum sustains. Confidence is improving after Wockhardt's exit from US generics and a credit rating upgrade. Q2 earnings in November are seen as the next big trigger.